

## ASX Release

### 2023 Annual General Meeting – Address by Executive Chair

Adelaide, 10 November 2023: Anatara Lifesciences (ASX: ANR or “the Company”) present the address and presentation by the Executive Chair, Dr David Brookes.

Dear Shareholders,

The recent Company news flow has been dominated by the completion of Stage 1 of the GaRP-IBS trial. As you are aware from the ASX updates, the results were considered very encouraging and the interim analysis of Stage 1 successfully met all the intended objectives; being safety criteria, an efficacy signal for the primary endpoint of the IBS-SSS and a clear preferred dose for Stage 2 of the trial. While it is not my intention to reiterate the trial details that have been extensively covered in ASX releases and a recent webinar, I have prepared a brief presentation to refresh where we are at with a review of the results and some of the points recently raised during investor discussions.

The Annual Report was lodged on the 16<sup>th</sup> of October and has a Chair’s letter with a comprehensive Operations Report, which I do not intend to reiterate today as we focus on the current activities and the future. At present, Anatara has an entitlement issue in the form of a Rights Issue so as not to disadvantage any of our shareholders. There has been strong support from many major shareholders through firm commitments, which has been appreciated and, while it is too early in the process with the closure date of the Entitlement Issue being the 1st of December to offer any update today, it appears that the Rights Issue will raise the total of the funds sought.

We have a small, committed team around Anatara with a strong focus on creating shareholder value through quality projects. The immediate project for advancement is our **Gastrointestinal ReProgramming** (“GaRP”) to become a product for wide-ranging indications across GIT considerations via the completion of the IBS trial.

I will take this opportunity to thank Anatara’s management, Board members and contracted service providers for their unstinting effort and input, and again thank our loyal shareholders for their ongoing support.

Yours sincerely,



Dr David Brookes

Executive Chair



For more information please contact:

**Dr David Brookes**

Chair, Anatara Lifesciences Ltd

+61 (0) 411 712 579

[dbrookes@anatara.com](mailto:dbrookes@anatara.com)

**Dirk van Dissel**

Candour Advisory – Investor Relations

+61 (0) 408 326 367

[dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

**About Anatara Lifesciences Ltd**

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

**Disclaimer**

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited

Registered Office

C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000

Email [info@anatara.com](mailto:info@anatara.com) | Website [anataralifesciences.com](http://anataralifesciences.com)

